Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
RESEARCH TOOLSreports
Holding ZNTL?
Track your performance easily
ZNTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.16 - $18.07
Previous CloseN/A
Volume750.15K
Average Volume (3M)1.44M
Market Cap
$170.32M
Enterprise Value-$86.30M
Total Cash (Recent Filing)$25.15M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Feb 26, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding71,265,400
10 Day Avg. Volume2,001,358
30 Day Avg. Volume1,437,311
Standard Deviation0.22
R-Squared0.16
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.20
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.51
Enterprise Value/Revenue-2.13
Enterprise Value/Gross Profit-95.89
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$12.17Price Target Upside443.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Zentalis Pharmaceuticals News
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift
PremiumCompany Announcements
Zentalis Pharmaceuticals Advances with FDA Approval and Upcoming DataBulls Say, Bears Say
Bulls Say
Clinical ProgressAzenosertib's clinical progress has gained significant momentum, as evidenced by increased patient enrollment over the past year.
Leadership And StrategyJulie Eastland, who led Harpoon through its Merck acquisition, was appointed CEO, bringing valuable experience to Zentalis as it transitions to later stage development and commercialization.
Regulatory DevelopmentsThe FDA lifted the clinical hold on azeno and cleared the company to resume enrollment across all ongoing studies with no modifications to the original clinical development plan.
Bears Say
Clinical Trial IssuesThe hold was a result of two additional patient deaths due to sepsis in the setting of neutropenia in the DENALI study.
Safety ConcernsCaution remains on the benefit/risk of azeno and on prior management's development strategy which had extended timelines.
Stock PerformanceShares are down by 75% due to azeno's safety issues and deaths that resulted in the partial clinical hold.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $2.16 and its highest was $18.07 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $170.32M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 35 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.91 by $0.35.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.79.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,265,400 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.91. Following the earnings report the stock price went up 1.587%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Among the largest hedge funds holding Zentalis Pharmaceuticals’s share is Matrix Capital Management Company, LP. It holds Zentalis Pharmaceuticals’s shares valued at 51M.
---
Zentalis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.17 (443.30% Upside)
$12.17 (443.30% Upside)
Blogger Sentiment
Bullish
ZNTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 165.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.34%
12-Months-Change
Fundamentals
Return on Equity
-42.89%
Trailing 12-Months
Asset Growth
-23.06%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
---
ZNTL Stock 12 Month Forecast
Average Price Target
$12.17
▲(443.30% Upside)
Technical Analysis
Immunovant
―
Kura Oncology
―
RAPT Therapeutics
―
I-MAB
―
Fate Therapeutics
―
Theravance Biopharma
―
Best Analysts Covering ZNTL
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-46.17%
assigned a buy rating 2 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.17% per trade.
---